# OnCo record hypertension-and-proteinuria-on-vegf-pathway-inhibitors (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "hypertension-and-proteinuria-on-vegf-pathway-inhibitors" ;
  schema:name "High blood pressure and protein in the urine on VEGF-pathway inhibitors: monitoring, treatment and when to pause the cancer medicine"@en ;
  schema:alternateName "VEGF inhibitor hypertension"@en, "bevacizumab blood pressure"@en, "anti-angiogenic hypertension"@en, "TKI hypertension"@en, "proteinuria on bevacizumab"@en, "urine dipstick before bevacizumab"@en, "blood pressure on lenvatinib"@en, "blood pressure on axitinib"@en, "home blood pressure monitoring on cancer treatment"@en, "posterior reversible encephalopathy syndrome"@en, "PRES"@en ;
  schema:description "Medicines that block VEGF often raise blood pressure, sometimes within days, and can put protein in the urine. Your team checks your blood pressure before you start, asks you to measure it at home, tests your urine, and treats high readings so treatment can go on. Contact the hospital straight away for a headache that does not get better, confusion, drowsiness, a fit or changes in eyesight."@en ;
  schema:url <https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:tag "protocol", "cardio-oncology", "side-effect-management" ;
  onco:related <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/>, <https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/>, <https://onco.cc/protocols/hypothyroidism-on-tyrosine-kinase-inhibitors/>, <https://onco.cc/protocols/anti-vegf-drugs-around-surgery/>, <https://onco.cc/protocols/anticancer-drug-interaction-review/>, <https://onco.cc/key-papers/paper-lyon-eur-heart-j/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/tivozanib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/drugs/ponatinib/> ;
  onco:institutions <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/angiogenesis/>, <https://onco.cc/terms/cardiotoxicity/> .
